This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-02. Anything still debated is marked as such rather than presented as settled.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
In July 2020, the European Union granted a conditional marketing authorization for remdesivir with an indication for the treatment of COVID‑19 in adults and adolescents (aged twelve years and older with body weight at least 40 kilograms [88 lb]) with pneumonia requiring supplemental oxygen. In August 2022, the European Union granted a full marketing authorization for remdesivir.
==== Constitutive trafficking and changes in subunit composition ==== AMPA receptors are continuously being trafficked (endocytosed, recycled, and reinserted) into and out of the plasma membrane. Recycling endosomes within the dendritic spine contain pools of AMPA receptors for such synaptic reinsertion. Two distinct pathways exist for the trafficking of AMPA receptors: a regulated pathway and a constitutive pathway. In the regulated pathway, GluA1-containing AMPA receptors are trafficked to the synapse in an activity-dependent manner, stimulated by NMDA receptor activation. Under basal conditions, the regulated pathway is essentially inactive, being transiently activated only upon the induction of long-term potentiation. This pathway is responsible for synaptic strengthening and the initial formation of new memories. In the constitutive pathway, GluA1-lacking AMPA receptors, usually GluR2-GluR3 heteromeric receptors, replace the GluA1-containing receptors in a one-for-one, activity-independent manner, preserving the total number of AMPA receptors in the synapse. This pathway is responsible for the maintenance of new memories, sustaining the transient changes resulting from the regulated pathway. Under basal conditions, this pathway is routinely active, as it is necessary also for the replacement of damaged receptors. The GluA1 and GluA4 subunits consist of a long carboxy (C)-tail, whereas the GluA2 and GluA3 subunits consist of a short carboxy-tail.
== Post-translational modifications == Human C3orf52 is predicted to contain three phosphorylation sites at positions 140,180, and 183, two N-glycosylation sites at positions 106 and 159, and three O-linked glycosylation sites at positions 7, 26, and 37. All of the O-linked glycosylation sites are within the disordered region of this protein. This indicates that C3orf52 is a moderately regulated protein that likely functions more as a scaffold than as a structural protein.
Surface embalming, another supplemental method, utilizes embalming chemicals to preserve and restore areas directly on the skin's surface and other superficial areas as well as areas of damage such as from accident, decomposition, cancerous growths, or skin donation. There are many further miscellaneous procedures. For example, pacemakers are required to be removed if the body is to be cremated as the battery inside can explode and damage the cremator. Such are removed with one incision over the device, after which it may be extracted and discarded of properly. Surgical incisions are treated depending on their location and stage of healing. If the sutures are recent, a solution of phenol or other preservative chemicals is injected into the margins and the area disinfected. Metal sutures are removed after arterial injection, and the incision then tightly sutured with a running stitch. Sealing powder can be applied to protect against leakage, and glue is then applied over the surface of the incision. If the suture is visible, cyanoacrylate and/or a restorative suture is used. For feeding and breathing tubes, the skin around them may be destroyed and dented, and an embalmer may choose to use tissue builder or wax filler to restore the look and contour of the skin. Tracheotomy holes are left until after embalming as an outlet for purge before being permanently sealed, though they are closed with a saturated cotton ball to disinfect the opening and to contain any leakage during the arterial injection.
Modern-day diabetes is associated with two terms in the Chinese language. The traditional term, xiāo kě (消渴), means "wasting-thirst" and correlates closely with diabetes in most instances of historical description. The more modern term, táng niǎo bìng (糖尿病), means "sugar urine disease", and is equivalent to diabetes mellitus. It has been suggested that the modern term is derived from exchanges with Ayurvedic practitioners who called the condition madhumeha ("honey urine"). Within the Sinosphere (regions of East and Southeast Asia historically influenced by the linguistic and literary traditions of the Chinese empire), this etymology has also been borrowed into Korean (tang nyo byeong [당뇨병]) and Japanese (tou nyou byou [とうにょうびょう]). Reviews of diabetology history in Traditional Chinese medicine have classified the diagnosis and treatment of xiāo kě (消渴) into four periods, summarized below. Classic texts provided a typology of the condition and outlined various recommendations on diagnosis, development, treatment, and prevention. Knowledge of wasting-thirst was integrated with knowledge of diabetes during the Qing dynasty.
Sources: en.wikipedia.org
=== As an estrogen === DHEA is a weak estrogen. In addition, it is transformed into potent estrogens such as estradiol in certain tissues such as the vagina, and thereby produces estrogenic effects in such tissues.
== Antiviral drug resistance == Antiviral resistance can be defined by a decreased susceptibility to a drug caused by changes in viral genotypes. In cases of antiviral resistance, drugs have either diminished or no effectiveness against their target virus. The issue inevitably remains a major obstacle to antiviral therapy as it has developed to almost all specific and effective antimicrobials, including antiviral agents. The Centers for Disease Control and Prevention (CDC) inclusively recommends anyone six months and older to get a yearly vaccination to protect them from influenza A viruses (H1N1) and (H3N2) and up to two influenza B viruses (depending on the vaccination). Comprehensive protection starts by ensuring vaccinations are current and complete. However, vaccines are preventative and are not generally used once a patient has been infected with a virus. Additionally, the availability of these vaccines can be limited based on financial or locational reasons which can prevent the effectiveness of herd immunity, making effective antivirals a necessity. The three FDA-approved neuraminidase antiviral flu drugs available in the United States, recommended by the CDC, include: oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab). Influenza antiviral resistance often results from changes occurring in neuraminidase and hemagglutinin proteins on the viral surface. Currently, neuraminidase inhibitors (NAIs) are the most frequently prescribed antivirals because they are effective against both influenza A and B.
== Synthesis == The synthesis of metal carbonyls is a widely studied subject of organometallic research. Since the work of Mond and then Hieber, many procedures have been developed for the preparation of mononuclear metal carbonyls as well as homo- and heterometallic carbonyl clusters.
=== Intraocular viscoelastic injection === It is used as an aid in ophthalmic surgery acting as aqueous and vitreous humor, e.g. in cataract extraction (intra- and extracapsular), intraocular lens implantation, corneal transplant, glaucoma filtration, and retina attachment surgery and in the treatment of dry eyes. In surgical procedures in the anterior segment of eyeball, instillation of sodium hyaluronate its viscoelasticity enables maintenance of a deep chamber during surgical manipulation since the solution does not flow out of the open anterior chamber, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues. Its viscoelasticity also helps to push back the vitreous face and prevent formation of a postoperative flat chamber. In posterior segment surgery, sodium hyaluronate serves as a surgical aid to gently separate, maneuver, and hold tissues. It creates a clear field of vision, facilitating intra-operative and post-operative inspection of the retina and photocoagulation.
Sources: en.wikipedia.org
== Other uses == Recurrent pyogenic cholangitis, a medical condition Red Paraguaya de Comunicación, a TV operator in Paraguay Rei Publicae Constituendae, part of the title of the members of the Second Triumvirate, appearing on Roman coins République populaire de Chine, República popular China, República popular da China, the French, Spanish and Portuguese names for the People's Republic of China RPC, a Panamanian national television network
A break in the murder case of "Motamed" occurred when prosecutors got their hands-on text messages after they were able to unlock a decrypted cell phone from one of the participants in the plot. The two hitmen were discovered to have extensive criminal records and longstanding ties to organised crime. The text messages showed they were monitoring "Motamed", and had no clue why he was targeted, only that they were assigned with the task and were eager to get the job done. In April 2019, they were sentenced to 25 and 20 years of imprisonment for their roles in the murder. The messages also implicated "Noffel", who was found guilty for ordering the murder and sentenced to life in prison for his involvement in this hit. However, all three suspects remain silent about any of their involvement in this case. Dutch investigators were baffled when it became clear that the killers of "Motamed" were working on the orders of the Dutch-Moroccan crime boss "Noffel", a close associate of Ridouan Taghi. The Dutch government sees "Motamed" as the link between Taghi and the Iranian secret service. However, the execution of Mohammad-Reza Kolahi ("Ali Motamed") was not the only murder in which the Dutch government accuses Iran of being involved in. In 2017, an assassin shot several bullets into Ahmad Mola Nissi, the leader of the Iranian separatist group Arab Struggle Movement for the Liberation of Ahwaz. Nissi died in front of his house in The Hague, after living in the Netherlands for over a decade.
== Structure == ACTH consists of 39 amino acids, the first 13 of which (counting from the N-terminus) may be cleaved to form α-melanocyte-stimulating hormones (α-MSH) (this common structure is responsible for excessively tanned skin in Addison's disease). After a short period of time, ACTH is cleaved into α-melanocyte-stimulating hormone (α-MSH) and CLIP, a peptide with unknown activity in humans. In the human body, total weight ACTH is 4540 Da.
A pharmacologically important aspect of the contraction-reducing properties of ingested salvinorin A on gut tissue is that it is only pharmacologically active on inflamed and not normal tissue, thus reducing possible side-effects.
Humira is also submitted for global regulatory approval for psoriasis (the fifth Humira disease indication). Humira achieved more than US$3 billion in worldwide Humira sales. 2007: Abbott opens new biotechnology manufacturing facility in Puerto Rico 2008: Humira made available as a treatment for plaque psoriasis 2009: Five-year data indicate that the initial use of Humira co-administered with methotrexate may prevent further joint damage in early rheumatoid arthritis patients 2012: Humira possibly associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease 2013: Due to the separation of Abbott's research-based pharmaceuticals business unit, AbbVie acquires the rights to Humira. 2014: Humira recognized by IMS Health as the "world's best selling drug". 2014: In December 2014, Indian drugmaker Cadila Healthcare (as of 2022, Zydus Pharmaceuticals) announced the first adalimumab biosimilar drug at a fifth of its American price. The generic was launched under the brand name Exemptia. 2015: Humira made available for moderate to severe hidradenitis suppurativa, an orphan indication. At the time, no other treatment had been rigorously tested and found to be safe and effective in treating Hurley Stage II and Hurley Stage III disease.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.